Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 RSVPreF3 OA vaccine immunobridging and safety study in adults 50-59 years versus adults 60 years and older
NL-OMON53679Phase 3Active, not recruiting
- Sponsor
- GSK
- Start
- Dec 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in respiratory syncytial virus disease (RSV) comparing RSVPreF3 OA vaccine with Placebo (2 arms). Primary endpoints: RSV-A neutralization GMT ratio, RSV-A seroresponse rate difference and 2 more. Started Dec 2022; status: active, not recruiting.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on NL-OMON53679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53679.